ClinicalTrials.gg
Enrolling by invitationNCT05404503QuiCoUpdated Jan 6, 2026

Analysis of the Incidence of Cholangiocarcinoma on Choledochal Cyst in a Western Center

An observational study in Incidence of Cholangiocarcinoma on Choledochal Cysts, Postoperative Complications in Choledochal Cysts and Choledochal Cyst Monitoring, sponsored by María Teresa Moreno Asencio. Enrolling by invitation at 1 site in Spain. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by María Teresa Moreno Asencio · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
300
Sex
All
01

Study summary

Choledochal cysts are congenital cystic dilatations of the intra and/or extrahepatic bile duct. They have been considered a rare entity of the child population. Globally, they account for 1% of all biliary pathology benign, with a clearly higher incidence in Asian countries (1/5,000 in China, 1/1,000 in Japan, compared to 1/100,000-150,000 in Western countries). However, the number of adults diagnosed in recent years has increased by up to 70% due to improvements in imaging tests.

Currently, the common bile duct malformation is considered a premalignant entity: although the data are not very precise, it is estimated that between 2.6% and 26% of patients diagnosed choledochal cyst, will develop cholangiocarcinoma. In this sense, we must bear in mind that most of the published literature is of Asian origin, where the rate of cholangiocarcinoma is 0.1-71/100,000 compared to 0.1-1.8/100,000 in Europe or 0.6-1/100,000 in the USA.

The most used classification to differentiate the types of cysts is that of Todani. Following this classification, we would find a higher rate of malignancy on types I and IV.

The recommendations found in the literature refer to the need for surgical intervention for choledochal cysts due to their high rate of malignancy. These recommendations are based on studies conducted in a symptomatic Asian population. We do not usually find in therapeutic algorithms the inclusion of various factors that could be involved in the development of malignancy such as episodes of cholangitis, presence of anomaly in the pancreatobiliary junction, presence of lithiasis in cystic dilatation, etc.

Some surveys carried out among the scientific population reflect a lack of consensus on its management: in the same clinical situation, different surgery units specialized in hepatobiliary-pancreatic pathology would act in the opposite way (specifically surgical versus conservative treatment).

Bile duct resection is not without complications, both short-term and long-term. Therefore, the patient's symptoms, age or comorbidities can play an important role in decision-making in the treatment of this pathology.

This nationwide multicenter retrospective observational study aims to determine the clinical situation of this rare pathology in a Western environment.

A retrospective analysis of patients diagnosed with choledochal cyst in the period between 2000 and 2020 is proposed. Demographic variables, risk factors for cholangiocarcinoma, symptoms associated with the cyst and its characteristics, diagnostic method, type of treatment, complications will be analyzed. Malignancy, time, and follow-up method will also be discussed.

This study will attempt to answer questions about the incidence of choledochal cysts in our environment, their association with cholangiocarcinoma, the associated morbidity and mortality, as well as the therapeutic and follow-up attitudes adopted in the face of this rare pathology.

02

Conditions studied

  • Incidence of Cholangiocarcinoma on Choledochal Cysts
  • Postoperative Complications in Choledochal Cysts
  • Choledochal Cyst Monitoring

Keywords

  • cholangiocarcinoma, choledochal cysts, surgery
03

In context

Cholangiocarcinoma

824 studies on the registry are indexed under Cholangiocarcinoma; 287 are open to participants now.

This study's planned enrollment of 300 is above the median of 196 across 161 observational studies indexed under Cholangiocarcinoma.

Browse Cholangiocarcinoma studies →

Lead sponsor

This is the only study on the registry with María Teresa Moreno Asencio as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with a radiological diagnosis of choledochal cyst. Those patients diagnosed by the radiology service are included

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- A radiological diagnosis (diagnosed by the radiology service) of choledochal cyst, understood as a dilatation of the extra or intrahepatic bile duct (fusiform or saccular, following the Todani classification)

Exclusion criteria

Exclusion Criteria:

  • An objectified obstructive cause that justifies a dilatación of bile duct (lithiasis, papillitis or neoplasia)
  • A definitive imaging test that rules out an initial diagnosis of choledochal cyst.
  • Intraoperative diagnosis of choledochal cyst without subsequent radiological confirmation.
  • Patients with cystic lesions of another nature (biliary cysts, simple cysts, cystic neoplasms).
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Choledochal cyst and cholangiocarcinoma

    to analyze the incidence of cholangiocarcinoma in choledochal cysts

    Time frame: 20 years

07

Study locations

1 site
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05404503
Lead sponsor
María Teresa Moreno Asencio
Responsible party
María Teresa Moreno Asencio (MorenoAsencioM, Fundación Andaluza Beturia para la Investigación en Salud) — Principal investigator
First posted
Jun 3, 2022
Start date
Oct 1, 2022
Primary completion
Jan 1, 2025
Completion
Dec 1, 2026 (estimated)
Last update
Jan 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion